Anti-Human CXCR4 (Clone 12G5) – Purified in vivo GOLD™ Functional Grade

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

12G5 activity is directed against human CXCR4 (CD184; Fusin).

CXCR4 is expressed in various organs including ovary, bone marrow, kidney, lung, small intestine, spleen, lymph nodes, brain, stomach, liver, thymus, heart, and pancreas as well as on the surface of endothelial mature and precursor cells and pericytes.

CXCR4 is a G-protein coupled receptor that binds the chemokine CXCL12¹. Chemokines are small 8-12 kDa proteins that mediate cell migration and arrest, homing and trafficking of leukocytes in bone marrow and lymphoid organs, tissue formation, cytoskeletal rearrangement, and immune cell recruitment to inflammation. Additionally, chemokines are expressed by cancer cells, where they enhance tumor angiogenesis and development. CXCR4 is the chemokine receptor most abundantly expressed² and most frequently detected³ in various cancer types, being present in malignant cell subpopulations in primary tumors as well as sites of metastasis. CXCR4 is involved in tumor cell proliferation and migration² and is involved in leukocyte chemotaxis in several autoimmune diseases¹. CXCR4 also acts as an alternative receptor for some isolates of HIV-2 in the absence of CD4⁴. CXCR4 expression is regulated by HIF-1α, IL-5, IFN-γ, TGF-β, and IL-17A¹.

12G5 was produced by immunizing Balb/c mice with CP-MAC-infected Sup-T1 cells⁴. Hybridomas were generated and screened for the ability to inhibit CP-MAC-induced syncytium induction on Sup-T1 cells.

12G5 binds specifically to both human and nonhuman cells that express recombinant CXCR4⁴. 12G5 inhibits CD4-independent infection by some HIV-2 isolates, and preincubating cells with 12G5 abolishes syncytium formation. HIV-2/vcp-infected cells display a marked and selective reduction in 12G5 binding. 12G5 also inhibits induction of cell-to-cell fusion of CXCR4⁺ RD/CD4 cells by HIV-1 and HIV-2 strains⁵.

1. Mousavi A. Immunol Lett. 217:91-115. 2020.
2. Barbieri F, Bajetto A, Thellung S, et al. Expert Opin Drug Discov. 11(11):1093-1109. 2016.
3. Bajetto A, Barbieri F, Dorcaratto A, et al. Neurochem Int. 49(5):423-432. 2006.
4. Endres MJ, Clapham PR, Marsh M, et al. Cell. 87(4):745-756. 1996.
5. McKnight A, Wilkinson D, Simmons G, et al. J Virol. 71(2):1692-1696. 1997.
6. Fischer T, Nagel F, Jacobs S, et al. PLoS One. 3(12):e4069. 2008.
7. Volin MV, Joseph L, Shockley MS, et al. Biochem Biophys Res Commun. 242(1):46-53. 1998.
8. Berndt C, Möpps B, Angermüller S, et al. Proc Natl Acad Sci U S A. 95(21):12556-12561. 1998.
9. Ullrich CK, Groopman JE, Ganju RK. Blood. 96(4):1438-1442. 2000.
10. Murga M, Fernandez-Capetillo O, Tosato G. Blood. 105(5):1992-1999. 2005.